AR121913A1 - Compuestos terapéuticos - Google Patents

Compuestos terapéuticos

Info

Publication number
AR121913A1
AR121913A1 ARP210101081A ARP210101081A AR121913A1 AR 121913 A1 AR121913 A1 AR 121913A1 AR P210101081 A ARP210101081 A AR P210101081A AR P210101081 A ARP210101081 A AR P210101081A AR 121913 A1 AR121913 A1 AR 121913A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
heteroaryl
alkoxy
optionally substituted
Prior art date
Application number
ARP210101081A
Other languages
English (en)
Spanish (es)
Inventor
Cathy Louise Lucas
Eileen Mary Seward
George Hynd
Emma Louise Blaney
Barrie Phillip Martin
Thorsten Nowak
Nicholas Charles Ray
Simon Ross Crumpler
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of AR121913A1 publication Critical patent/AR121913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP210101081A 2020-04-22 2021-04-22 Compuestos terapéuticos AR121913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005852.5A GB202005852D0 (en) 2020-04-22 2020-04-22 Therapeutic compounds

Publications (1)

Publication Number Publication Date
AR121913A1 true AR121913A1 (es) 2022-07-20

Family

ID=70859963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101081A AR121913A1 (es) 2020-04-22 2021-04-22 Compuestos terapéuticos

Country Status (16)

Country Link
US (1) US20230159511A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139295B1 (cg-RX-API-DMAC7.html)
JP (1) JP7751165B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004722A (cg-RX-API-DMAC7.html)
CN (1) CN115667242B (cg-RX-API-DMAC7.html)
AR (1) AR121913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021258539A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021370A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174360A1 (cg-RX-API-DMAC7.html)
ES (1) ES3031970T3 (cg-RX-API-DMAC7.html)
GB (1) GB202005852D0 (cg-RX-API-DMAC7.html)
IL (1) IL297440A (cg-RX-API-DMAC7.html)
MX (1) MX427961B (cg-RX-API-DMAC7.html)
PH (1) PH12022552773A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214472A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211464B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207469A (en) 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds
WO2023073364A1 (en) 2021-10-25 2023-05-04 C4X Discovery Limited Tetrahydroisoquinoline compounds that are keap1 binders
CR20240325A (es) * 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2
WO2024130411A1 (en) * 2022-12-21 2024-06-27 Variational Ai Inc. Protease inhibitors and methods of using same
EP4696692A1 (en) * 2023-06-19 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
EP4596534A1 (en) * 2024-01-31 2025-08-06 University of Copenhagen Noncovalent small-molecule inhibitors of the keap1-nrf2 interaction
WO2025237912A1 (en) 2024-05-13 2025-11-20 Astrazeneca Ab Keap1 inhibitors for use in the treatment of bronchiectasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
KR20180017038A (ko) * 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
MY207469A (en) * 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds

Also Published As

Publication number Publication date
CN115667242B (zh) 2025-02-28
AU2021258539A1 (en) 2022-11-10
WO2021214472A1 (en) 2021-10-28
GB202005852D0 (en) 2020-06-03
JP2023524207A (ja) 2023-06-09
JP7751165B2 (ja) 2025-10-08
EP4139295B1 (en) 2025-04-09
BR112022021370A2 (pt) 2022-12-06
ES3031970T3 (en) 2025-07-14
PH12022552773A1 (en) 2024-03-25
CA3174360A1 (en) 2021-10-28
US20230159511A1 (en) 2023-05-25
MX2022013396A (es) 2022-12-13
EP4139295A1 (en) 2023-03-01
MX427961B (es) 2025-10-13
ZA202211464B (en) 2025-05-28
IL297440A (en) 2022-12-01
CN115667242A (zh) 2023-01-31
KR20230004722A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
AR111776A1 (es) Heteroarilos inhibidores de las proteínas ras mutantes de g12c
AR126406A2 (es) Compuestos de tetrazolinona y su uso
AR096643A1 (es) Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo)
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR091368A1 (es) Compuestos y composiciones para modular la actividad de egfr
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR109905A1 (es) Pirrolidinas sustituidas como moduladores de cftr
AR114083A2 (es) AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
AR055630A1 (es) Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias.
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR104259A1 (es) Inhibidores de bromodominio
AR099936A1 (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
AR113886A1 (es) Derivados de indol macrocíclicos
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR088989A1 (es) Derivados biciclicos de dihidroisoquinolin-1-ona
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR110227A2 (es) Derivados de pirazol con acción sobre fgf
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR091464A1 (es) Compuestos biciclicos de tiofenilamida
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR113888A1 (es) Derivados de indol macrocíclicos sustituidos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100706A1 (es) Derivados de naftiridinadiona
AR117037A1 (es) Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias